Sandoz’s biosimilars could be a draw for would-be suitors 

As Novartis weighs what’s next for Sandoz, the generics and biosimilars unit could have growth drivers on the way in the form of a biosimilars portfolio that the pharma hopes will deliver $3 billion in 2025 sales.  

Sandoz’s continued struggles with pricing pressure and the effects of the pandemic have pushed Novartis AG (NYSE:NVS; SIX:NOVN) to formally explore strategic alternatives for the business, including a separation...